CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of CG Oncology, Inc. (NASDAQ:CGON) have been assigned a consensus rating of “Moderate Buy” from the fourteen research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $69.00.

Several equities analysts have recently weighed in on the company. Royal Bank Of Canada lifted their price objective on CG Oncology from $61.00 to $73.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Wedbush started coverage on CG Oncology in a research note on Thursday, December 11th. They set an “outperform” rating and a $70.00 target price for the company. Weiss Ratings restated a “sell (d-)” rating on shares of CG Oncology in a report on Wednesday, January 21st. Morgan Stanley set a $93.00 price target on shares of CG Oncology in a research note on Friday, January 9th. Finally, HC Wainwright upped their price target on shares of CG Oncology from $75.00 to $80.00 and gave the company a “buy” rating in a report on Friday, February 27th.

CG Oncology Stock Performance

Shares of CG Oncology stock opened at $64.62 on Wednesday. The stock’s fifty day simple moving average is $58.01 and its 200 day simple moving average is $47.33. The company has a market capitalization of $5.46 billion, a PE ratio of -31.22 and a beta of 1.18. CG Oncology has a 12 month low of $14.80 and a 12 month high of $69.35.

CG Oncology (NASDAQ:CGON) last posted its earnings results on Friday, February 27th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The business had revenue of $2.32 million during the quarter. Analysts predict that CG Oncology will post -1.31 EPS for the current fiscal year.

Insiders Place Their Bets

In other CG Oncology news, Director James Mulay sold 11,145 shares of the stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of CGON. Wellington Management Group LLP raised its position in CG Oncology by 190.3% in the 3rd quarter. Wellington Management Group LLP now owns 5,512,779 shares of the company’s stock valued at $222,055,000 after buying an additional 3,613,885 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in CG Oncology by 116.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock worth $142,961,000 after acquiring an additional 1,854,386 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in shares of CG Oncology during the 4th quarter worth approximately $62,909,000. Bank of America Corp DE grew its stake in shares of CG Oncology by 409.9% during the 2nd quarter. Bank of America Corp DE now owns 1,736,769 shares of the company’s stock worth $45,156,000 after acquiring an additional 1,396,170 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of CG Oncology by 46.4% in the fourth quarter. State Street Corp now owns 2,996,695 shares of the company’s stock valued at $124,423,000 after purchasing an additional 950,028 shares during the last quarter. 26.56% of the stock is currently owned by institutional investors.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.